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BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma.
Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant
treatment. The test most frequently applied is based on detecting TP53 mutations, but alternative methodology is required for cases
that harbour the wild-type gene.
METHODS: One hundred and two cases with tumour-adjacent margins, considered to be clear margins by microscopy, were examined
using carefully optimised molecular diagnostics based on detection of the TP53 and Ly-6D markers. The markers were also combined
to provide a dual approach.
RESULTS: The dual molecular diagnostic identified cases with a significant increase in the probablility of developing locoregional
recurrence when tumour-adjacent positive and clear margins were compared (P¼ 0.0001). These tests were most useful when the
clearance at the resection margins was 5mm or less. The TP53-based diagnostic was a better predictor of locoregional recurrence
than established clinicopathological parameters.
CONCLUSION: The optimised TP53-based diagnostic rapidly identifies an important subgroup of cases with close margins that will
benefit from new treatment modalities to reduce the risk of recurrence.
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Oral squamous cell carcinomas (OSCC) arise in genetically altered
fields, of which only a small group can be identified clinically as a
white or red patch. Many more are recognised microscopically as
dysplasia. Locoregional recurrence is the major cause of treatment
failure after surgery for OSCC. Recurrence may develop due to
evolution of a new focus of carcinoma in a field that has not been
excised. Alternatively, tumour spread beyond the resection
margins that was not identified by histological examination may
be the source of cells responsible for this recurrence. Application
of ultrasensitive diagnostics based on finding carcinoma-
associated mutations in the surrounding normal tissue may reveal
the extent of spread of genetically altered keratinocytes, or residual
carcinoma to identify cases at high risk of recurrence after surgery
(Brennan et al, 1995; Partridge et al, 2000; van Houten et al, 2002;
van Houten et al, 2004; Huang et al, 2007).
The TP53 gene is frequently chosen as a target for detection
of precancerous change and minimal residual carcinoma as it is
mutated in 50–60% of OSCC and a rate-limiting step in this
process (Smeets et al, 2011). However, these mutations may occur
anywhere in this gene, such that diagnostics for assessment of
tumour-adjacent margins, based on detecting the same TP53
mutation in a carcinoma and the surrounding normal tissues, must
be customised for each different mutation. Development of a
method to achieve a sensitivity for TP53 mutation detection of at
least one mutant transcript in 1000 wild-type, and ideally 1 in
10 000, requires multistep molecular techniques, as quantitative
reverse-transcription PCR (QRT-PCR) cannot detect mutant TP53
against a large background of wild type. Preliminary studies
applying new methods to detect TP53 mutations in tumour-
adjacent normal tissues often appear promising but may be limited
to analysis of selected cases for which a custom test is available
(Shi et al, 2004; Poeta et al, 2009). Larger studies often reveal the
need for further optimisation to achieve reproducible and robust
assays with a high sensitivity for mutation detection. Once these
goals are achieved, molecular diagnostics provide the clinician
with a powerful new resource that can give information about the
risk of recurrence within a short time frame.
There is also a need to develop ways to identify precancerous
fields where progression is likely and tumour spread when TP53 is
wild type. Until other highly recurrent carcinoma-specific muta-
tions are identified, application of a surrogate marker for
carcinoma, based on the detection of a squamous cell-specific
target Ly-6D, recognised by the E48 antibody and often termed
Ly-6D, in the deep tissues has been proposed (Nieuwenhuis et al,
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2003; Graveland et al, 2009). This antigen has been shown to be
expressed by normal, transitional and malignant squamous
epithelia (Quak et al, 1990) and 80–90% of OSCC (Graveland
et al, 2009). The importance of molecular screening of deep as well
as mucosal margins was established by Huang et al (2007) and
provides a rational basis to include the Ly-6D-based approach a
surrogate marker so that all cases can be tested.
In this report, we present our findings utilising this dual
approach in a prospective clinical trial powered to establish
whether the molecular tests identify cases with a 20% increase in
the risk of recurrence 2 years post surgery.
MATERIALS AND METHODS
One hundred and forty cases undergoing resection of OSCC were
recruited to the UKCRNID7493 clinical trial. The Research Ethics
Committees approved this prospective study at all collaborating
centres. Tissue samples were collected as previously described
(Huang et al, 2007). Briefly after tumour resection, the surgeon
excised mucosal and deep tumour-adjacent margins from the tissues
remaining at the edge of the defect for molecular examination. When
the base of the resection was in continuity with the neck dissection
and there were no true deep tumour-adjacent margins, the samples
analysed were excised from the lateral aspects of the defect. An equal
number of mucosal and deep margins were collected for each
carcinoma. Each margin was divided into two halves. One part was
snap frozen in isopentane for molecular analysis, the other part was
fixed in formalin and processed into paraffin for examination of step-
serial sections by light microscopy. A portion of each carcinoma was
snap frozen and stored at  80 1C until nucleic acids were extracted.
The minimum tumour clearance at the mucosal and deep margins
was also reported by the pathologist. One hundred and two cases,
with resection and tumour-adjacent margins assessed as being
carcinoma-free by light microscopy, were forwarded for molecular
analysis. All cases were followed for a minimum of 24 months to
assess the impact of the molecular diagnostics on recurrence. Distant
metastases were not analysed, as the study aim was to assess the effect
of positive tumour-adjacent margins on the rate of recurrence.
Examination of mucosal and deep tumour-adjacent
margins for cases where the carcinoma harboured
mutant TP53
TP53 mutation status was established (Huang et al, 2007), and the
presence or absence of the same TP53 mutations in the matched
tumour-adjacent margins was also established using the LigAmp
assay (Shi et al, 2004; Poeta et al, 2009) with the following
important refinements. To develop the LigAmp assay for each
TP53 mutation, the relevant exon was PCR amplified and purified
for all carcinomas and the tumour-adjacent margins to be tested.
Serial dilutions of each carcinoma-derived TP53 cDNA were
diluted in the corresponding wild-type cDNA prepared from
normal oral mucosa. Tumour-adjacent margins were processed
undiluted. Optimal conditions for the ligations were 109 TP53
amplicons in 1 ml combined with 2.5 ml 10 pfu ligase buffer,
0.5ml 4 Uml 1 pfu ligase (Stratagene, Agilent Technologies,
Stockport, UK), 0.25ml 4 mM upstream ligation oligonucleotide
(containing the nucleotide complementary to the TP53 mutation
and a mismatched G or T, at the third base from the mutation site
when feasible), 0.125 ml 4 mM downstream TP53-specific oligonu-
cleotide and 20.125 ml nuclease-free water. The subsequent QRT-
PCR reaction was performed with 50 nM of M13-specific primers,
with each sample analysed in triplicate using an AB 7700 detection
system (Applied Biosytems, Warrington, UK). Primer sequences
that amplify TP53 mutations with a sensitivity greater than I
mutant copy in 10 000 wild type are shown in Supplementary
Table 1.
Molecular margins were scored as TP53 mutation-positive or -
negative according to the 88–95–99.7% rule, using the formula
Nct 3NSD¼X (where Nct is the mean of the normal tissue cycle
threshold values and NSD is the s.d. of the normal ct value).
A margin was scored as TP53 mutation-positive when the ct was
less than X (Flys et al, 2005). All cases were analysed using gDNA
and cDNA, and positive results validated from new tissue sections.
Cases with at least one positive tumour-adjacent mucosal or deep
margin were considered to have a positive molecular test.
Examination of deep tumour-adjacent margins for cases
wherein the carcinoma harboured wild-type TP53
Deep margins for cases where the carcinoma was wild type for
TP53 were analysed for expression of Ly-6D by QRT-PCR, as
previously described (Nieuwenhuis et al, 2003; Graveland et al,
2009), using the two-standard curve method for data analysis.
YHAWS was selected as the internal reference, as the expression of
this gene is stable across a broad range of oral tissues (n4250).
For primer sequences, see Supplementary Table 2. The threshold
level of Ly-6D expression above which deep margins were scored
as positive was defined as the mean ct and s.d. using 30 normal
samples harvested from different tissue types, including muscle,
minor salivary glands and oral submucosa.
The dual approach
The TP53 and Ly-6D markers were also combined in a dual
approach in which a positive score with one marker provided a
positive molecular test.
Statistical analysis
Data was analysed using Stata Release 11.1 (StataCorp, College
Station, TX, USA). Significance was pre-determined at a¼ 0.05.
Monte Carlo simulations were used to obtain exact probabilities
(Good, 2006). Single-ordered data was analysed using the Kruskal–
Wallis test and ‘survival’ data was analysed by the Kaplan–Meier
survival curves in conjunction with the log rank test. Proportional
hazard models were used to determine the univariate prognostic
significance of clinicopathological variables and molecular diag-
nostics with respect to local and locoregional recurrence. P-values
for hazards ratios (HRs) were calculated using the likelihood-ratio
test relative to a reference group. Multivariate analysis logistic
regression was also applied with model parameter selection based
on Bayesian information (Raftery, 1995).
RESULTS
The clinical and pathological features of 102 cases with carcinoma-
free resection margins are shown in Table 1. Forty-six cases received
post-operative radiotherapy. The follow-up time for the study ranged
from 24 to 146 months, with the median being 43 months. At the
time of assessment, 16 out of 102 cases developed local and 27 out of
102 cases developed locoregional recurrence (Table 1). Fifty-one
carcinomas harboured mutant TP53 and 51 were wild type. Three
recurrent TP53 mutations were identified (175.2 G-A, 282.1 C-T and
248.2 G-A) with each detected for three cases.
Analysis of mucosal and deep tumour-adjacent margins
Forty-two LigAmp TP53 assays were optimised for 51 cases.
Thirty-three assays had a sensitivity for TP53 mutation detection
greater than I mutant amplicon in 10 000 wild type, with the
sensitivity for the remaining mutations being greater than 1 in
1000. Careful optimisation of the reaction conditions for the
ligation and QRT-PCR steps for each mutation ensured that each
customised test was robust, reproducible and achieved high
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sensitivity for TP53 mutation detection. Once optimised for a
specific TP53 mutation, a test result could be available within 3
working days. Subsequently, 111 mucosal tumour-adjacent mar-
gins and 97 deep margins were analysed. For representative
example, see Supplementary Figure 1. Thirty-four of the 51 cases
(66.6%) showed TP53 mutations in one or more margins
examined. Eight of the 51 cases had only mucosal margins that
were scored as TP53 mutation-positive, 8 had only TP53 mutation-
positive deep margins and 18 were positive at both sites. Eleven of
the 26 (42%) positive had morphological evidence of dysplasia at
the margins of the resected carcinoma, and 6 of 26 (15.3%) showed
dysplasia at the tumour-adjacent mucosal margins.
Overall, there was excellent concordance of the LigAmp assay
when gDNA and cDNA were analysed with three cases showing
discordant results for one or more of the four margins tested, but
the overall score for these cases was unchanged (Supplementary
Table 3).
Fifty-one cases, wherein the tumour harboured wild-type TP53,
with 94 deep tumour-adjacent margins, which could not be
examined with the TP53 LigAmp, were analysed with the surrogate
tumour marker Ly-6D, and 14 cases were scored as having positive
margins.
A subgroup of cases wherein the tumour harboured mutant
TP53 was analysed with both the TP53 LigAmp and the Ly-6D
QRT-PCR assay (n¼ 30). All available deep tumour-adjacent
margins were tested. Concordant results were observed for
10 cases, with the margins scored as positive with both tests for
6 cases and negative for the other 4. A further 10 cases were TP53
mutation-positive but Ly-6D negative; the other cases were Ly-6D-
positive but TP53-negative.
No immunostained cells with morphological features considered
to be adequate to categorically diagnose minimal residual
carcinoma were identified in the part of each margin forwarded
for immunohistology, although normal squamous epithelia was
reported in deep margins (n¼ 4).
Relationship between molecular analysis of tumour-
adjacent margins and locoregional recurrence
A high number of cases with TP53 mutation-positive tumour-
adjacent margins developed locoregional recurrence, 16 out of 34
(47%; Table 1). The effect of TP53 mutation-positive margins on
locoregional recurrence was assessed by Kaplan–Meier estimates
and log rank tests. This analysis revealed that the probability of
developing locoregional recurrence was significantly higher for the
group with TP53 mutation-positive margins when compared with
the group with clear margins (P¼ 0.0001; Figure 1A).
Fourteen of 51 (27%) cases wherein the carcinoma was wild type
for TP53 had deep margins scored as Ly-6D-positive. Two of these
cases developed local and 7seven developed locoregional recur-
rence, but the Kaplan–Meier estimates for the comparisons
between cases with Ly-6D-positive and -negative margins were
not significant.
The results obtained with both the TP53 and Ly-6D-based
diagnostics were also combined, so that all 102 cases were analysed
with a molecular test and the probability of developing locor-
egional recurrence was significant (P¼ 0.0001; Figure 1B). Detailed
analysis of the 102 cases examined with the combined diagnostics
revealed that when the clearance at the resection margins was
5mm or less, the difference in the recurrence rate with a positive
tumour-adjacent margin was significant for locoregional recur-
rence (P¼ 0.008; Figure 1C). In contrast, this difference was not
significant when the clearance at the resection margins was greater
than 5mm (P¼ 0.628).
When the value of testing tumour-adjacent mucosal or deep
margins was compared with the dual diagnostic, the difference in
the locoregional recurrence rate was significant when cases with
clear and positive deep margins were compared. The difference in
the recurrence rate was also significant when cases with clear and
positive mucosal and deep margins were compared (P¼ 0.017;
Figure 1D).
Concordance between TP53 mutation-positive and
LY-6D-positive tumour-adjacent margins, development
of recurrence and the effect of radiotherapy
The finding of TP53 mutation-positive tumour-adjacent margins
correctly identified 22 of 25 cases developing locoregional
Table 1 Clinicopathological details for 102 cases analysed with respect
to tumour TP53 gene status
TP53 mutant
cases
(n¼ 51)
Wild-type
cases
(n¼ 51)
All cases
(n¼ 102)
Age mean (range) 62 (34–90) 63 (36–82)
Gender
Male 32 32 64
Female 19 19 38
UICC stage
I or II 11 14 25
III or IV 40 37 87
Tumour stage
T1 or T2 11 14 25
T3 or T4 14 35 49
Lymph nodes
N0 21 21 42
N1 10 10 20
N2 19 17 36
N3 1 1
Resection margins clear at (mm)
2 46 39 85
3 34 35 69
5 22 20 42
Tumour differentiation
Well 16 16 32
Moderate 27 27 54
Poor 8 8 16
Vascular invasion 11 9 20
Neural invasion 18 10 28
Invasion pattern
Pushing 16 19 35
Infiltrative 35 32 67
Dysplasia at resection margin 19 14 33
Dysplasia at molecular margin 8 5 13
Post-operative radiotherapy
Yes 26 20 46
No 25 31 56
Recurrence
Local 9 7 16
Regional only 6 0 6
Local and regional 10 11 21
Alive at study end 20 29 49
DOC 5 3 8
DOD 24 19 43
Lost to follow-up 2 0 2
Abbreviations: DOC¼ died as a result of other causes; DOD¼ died of disease.
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recurrence. Fifteen of 17 cases with TP53 mutation-negative
margins and 17 of 34 cases with TP53 mutation-positive tumour-
adjacent margins did not develop recurrence, Table 2. These
relationships are also shown for the Ly-6D-based diagnostic and
the combined approach, together with the sensitivity, specificity,
positive and negative predictive values for recurrence.
It is to be expected that some cases with TP53 mutation-positive
or Ly-6D-positive margins will not develop recurrence due to the
effect of radiotherapy. Twenty-six of 51 (51%) cases wherein the
carcinoma harboured mutant TP53 received radiotherapy and 11
(42%) developed locoregional recurrence. The recurrence rate for
cases where the tumour was wild type for TP53 was slightly higher
in that 21 of 51 cases received radiotherapy and 11 of 21 (52%)
developed recurrences. However, overall, there was no difference
in the rate of recurrence for TP53 mutant and wild-type cases.
Relationship between clinicopathological features of
molecular examination of tumour-adjacent margins and
development of recurrence
A combination of factors is associated with treatment failure, so we
used univariate and HR analyses to look for relationships between
the molecular test and clinicopathological features (TNM stage,
T stage, N stage, tumour differentiation, perivascular or perineural
spread, infiltrative or pushing margins and dysplasia at the
resection margins) and development of recurrence.
Univariate analysis of the subset of TP53 mutant cases revealed
that a positive tumour-adjacent margin was the only significant
factor for locoregional recurrence (P¼ 0.002), whereas positive
tumour-adjacent margins (P¼ 0.002) and TNM stage (P¼ 0.035)
were significant for the full data set. In contrast, only perineural
spread was significant for locoregional recurrence (P¼ 0.032) for
the TP53 wild-type cases.
Application of HRs in survival analysis confirmed that a positive
molecular test was significant for locoregional recurrence for the
TP53 mutant cases, HR 4.8 (95% CI 1.66–14.2, P¼ 0.004;
Supplementary Table 4). The HR for the dual diagnostic was also
significant, HR 3.1 (95% CI 1.7–5.7, Po0.001). HR analysis
confirmed that perineural spread was a significant factor for
locoregional recurrence for the wild-type cases HR 2.28 (95% CI
8.59–6.08, P¼ 0.097).
In multivariate analysis, considering all clinicopathological
factors together with the results from the molecular tests, for the
cases where the carcinoma harboured mutant TP53, a positive
molecular test was the best independent predictor of locoregional
recurrence, followed by the combination of a positive molecular
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Figure 1 Kaplan–Meier estimates for (A) The TP53-based diagnostic, no locoregional recurrence with respect to the presence or absence of TP53
mutations in the tumour-adjacent margins examined. (B) No locoregional recurrence with the dual TP53- and Ly-6D-based diagnostic. (C) No locoregional
recurrence with the dual diagnostic for cases wherein the tumour-adjacent margins examined were from cases in which the clearance at the resection
margins was 5mm or less. (D) No local recurrence with the dual diagnostic with respect to clear tumour-adjacent margins, TP53 mutation-positive tumour-
adjacent mucosal margins, positive deep margins or positivity at both sites.
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test and perineural spread. When the TP53 wild-type cases were
considered, perineural spread remained the best predictor for
locoregional recurrence.
DISCUSSION
At present, the clinician relies on clinical staging and the
histopathology report to gauge a patient’s prognosis and plan
treatment. The challenge is to develop molecular markers that can
provide more accurate predictions about the risk of recurrence and
to establish which cases are most likely to benefit from the
additional information provided by new diagnostics. In the present
study, we successfully applied a dual molecular diagnostic to
identify cases with clear resection margins at high risk of
locoregional recurrence. We demonstrate for the first time that
the LigAmp TP53-based diagnostic outperforms all established
clinicopathological parameters for predicting the risk of locor-
egional recurrence. The result of this molecular test can now be
available within 3 working days, facilitating translation of this test
from a research to a routine diagnostic laboratory setting and
incorporation into future clinical trials of new adjuvants.
We also show that molecular assessment of tissues beyond the
resection margins identifies cases at high risk of local or
locoregional recurrence, and that the molecular diagnostics are
most useful when the clearance at the surgical margins is less than
5mm. The difference in the local recurrence rate was most
significant when cases with clear and tumour-positive deep
margins were compared, confirming the importance of applying
molecular tests to mucosal as well as deep margins. Our
observations also confirm the importance of perineural invasion
as a prognostic marker (Soo et al, 1986; Fagan et al, 1998; Rahima
et al, 2004). The concordant results when cDNA and gDNA were
used indicates that false-positive tests due to DNA leaking from
tumour cells is less of a concern than previously suggested (van
Houten et al, 2002), although we now routinely use cDNA as the
starting material for molecular diagnostics.
The TP53 LigAmp cannot be used to quantify the burden of
residual carcinoma for an individual case, only to score a tumour-
adjacent margin as positive or negative in relation to the threshold,
as the percentage of malignant cells in each carcinoma is different.
To address this point, Poeta et al (2009) used plasmids containing
mutant TP53 as well as carcinoma-derived DNA to quantify the
LigAmp assay, but their results were not significant. These authors
subsequently applied recursive partitioning trees based on
information about whether recurrence developed or not, to set
the cut point for deciding whether a test should be scored as
positive or negative. The Kaplan–Meier ‘survival’ analysis in this
earlier report must thus be interpreted with caution. However, the
present larger study based on an optimised methodology confirms
the clinical utility of this TP53-based diagnostic to provide a test
with a high sensitivity for mutation detection.
In contrast, the relatively quantitative Ly-6D-based test for
molecular analysis of deep margins lacks the discriminatory
sensitivity of the TP53-based diagnostics in terms of identifying
cases at risk of recurrence. Nevertheless, the high specificity of the
Ly-6D-based approach for predicting no risk of recurrence means
that a negative test provides useful information. Thus, combining
both molecular diagnostics allows consecutive cases to be screened
for evidence of minimal residual carcinoma, with the caveat that
only deep margins are examined with the Ly-6D QRT-PCR.
The high rate of false-positive tests obtained with the Ly-6D
QRT-PCR suggests that there are probably normal squamous
epithelia in the deep margins forwarded for analysis, and this was
confirmed by light microscopy. Contamination from normal cells
as the margins are harvested seems most likely, but as the
molecular and histological examination was performed on
different parts of each margin, no firm conclusions can be made.
Thus, although the Ly-6D-based diagnostic can provide useful
prognostic information, there are drawbacks associated with this
approach. This highlights the need to identify a highly recurrent
mutation, a fusion gene or an intragenic fusion, similar to the
markers that have been so successful in developing effective
strategies to monitor for the presence of residual leukaemia, to
develop an alternative robust molecular diagnostic for OSCC.
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